Ketamine for Methamphetamine Use Disorder (KMD)

This is a 12-week randomised, triple-blind, parallel-group trial comparing IV ketamine (0.50 mg/kg) to IV midazolam (0.02 mg/kg) delivered as eight infusions over six weeks in adults with moderate to severe methamphetamine use disorder.

All participants receive weekly medical management during weeks 1–6 and weekly cognitive behavioural therapy on non-infusion days for 12 weeks; outcomes include feasibility, safety, and efficacy to inform larger multi-site trials.